Market Cap
$395.7M
CINT
CI&T Inc
$3.21 ▲ +2.23%
Prev close $3.14Market cap$395.7M
ConsensusStrong Buy
12-mo target$5.62 (+75.1%)
▲ Bullish
Analyst conviction 8/10
Insider Buying Cluster (3 insiders) Software & IT
Snapshot
The big-picture read on CINT right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Analyst Consensus
Strong Buy (80%)
Insider Activity
$78.2K buy / $0.00 sell
Insider Net $
$78.2K
SEC Reports
1
Price chart 30d -8.5%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 1, 2026 Insider
Martins Fernando Matt Borges bought 4,123 shares
Director @ $3.18 ($13.1K)
Sep 30, 2026 Insider
Gon Cesar Nivaldo bought 2,849 shares
Chief Executive Officer @ $3.10 ($8.8K)
Sep 30, 2026 Insider
Guicardi Neto Bruno bought 800 shares
Pres. of N. Am. /Europe Ops @ $3.07 ($2.5K)
Aug 11, 2026 earnings_calendar
Apr 27, 2026 SEC CINT Q2 2026 Earnings Scheduled — 2026-08-11
CI&T Inc announced its Annual General Meeting (AGM) to be held on May 26, 2026, which will include the approval of the c
6-K — Impact 3/10
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
80% rate it Buy or better · 15 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Aug 12, 2026 | TD Cowen | MAINTAIN | Buy | 56% |
| Aug 12, 2026 | JP Morgan | MAINTAIN | Overweight | 55% |
| Aug 12, 2026 | UBS | MAINTAIN | Buy | 55% |
| Jul 21, 2026 | Wedbush | DOWNGRADE | Neutral | 57% |
| Jul 9, 2026 | TD Cowen | MAINTAIN | Buy | 56% |
| May 12, 2026 | UBS | MAINTAIN | Buy | 55% |
| May 12, 2026 | Wedbush | MAINTAIN | Outperform | 57% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 3 | 9 | 3 | 0 | 0 | 80% | |
| Aug 1, 2026 | 3 | 9 | 3 | 0 | 0 | 80% | |
| Jul 1, 2026 | 4 | 9 | 2 | 0 | 0 | 87% | |
| Jun 1, 2026 | 4 | 9 | 2 | 0 | 0 | 87% | |
| May 1, 2026 | 4 | 9 | 2 | 0 | 0 | 87% | |
| Apr 1, 2026 | 4 | 9 | 2 | 0 | 0 | 87% | |
| Mar 1, 2026 | 4 | 9 | 2 | 0 | 0 | 87% | |
| Feb 1, 2026 | 4 | 9 | 2 | 0 | 0 | 87% |
Price targets
Where 10 covering analysts think CINT trades over the next 12 months.
$5.62 +75.1% upside Strong Buy
Current$3.21 Low$4.00 Median$5.00 High$8.00 10 analysts
$4.00$8.00
Analyst rating None as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
1 SEC filing reports analyzed · 0 bullish, 0 bearish, 0 mixed, 1 neutral · avg impact 3.0/10.
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Aug 11, 2026
earnings_calendar
CINT Q2 2026 Earnings Scheduled — 2026-08-11
May 11, 2026
earnings_calendar
CINT Q1 2026 Earnings Scheduled — 2026-05-11
Mar 11, 2026
earnings_calendar
CINT Q4 2025 Earnings After Market Close — 2026-03-11
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $0.10 | $0.09–$0.11 | 7.8% | -13.0% | 0↑ 4↓ | $0.1B | 6 |
| Next Q | $0.11 | $0.10–$0.12 | -21.0% | -12.2% | 0↑ 3↓ | $0.1B | 6 |
| Current FY | $0.37 | $0.33–$0.42 | -4.5% | -7.7% | 0↑ 4↓ | $0.6B | 8 |
| Next FY | $0.44 | $0.41–$0.50 | 19.1% | -6.1% | 0↑ 3↓ | $0.6B | 8 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $0.097 | — |
| 7d ago | $0.110 | -0.013 |
| 30d ago | $0.111 | -0.014 |
| 60d ago | $0.111 | -0.014 |
| 90d ago | $0.111 | -0.014 |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
8 insiders, 27 transactions. Net $78.2K — $78.2K bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Oct 1, 2026 | Martins Fernando Matt Borges | Director | BUY | 4,123 | $3.18 | $13.1K |
| Sep 30, 2026 | Gon Cesar Nivaldo | Chief Executive Officer | BUY | 2,849 | $3.10 | $8.8K |
| Sep 30, 2026 | Guicardi Neto Bruno | Pres. of N. Am. /Europe Ops | BUY | 800 | $3.07 | $2.5K |
| Sep 29, 2026 | Gon Cesar Nivaldo | Chief Executive Officer | BUY | 3,835 | $2.95 | $11.3K |
| Sep 29, 2026 | Guicardi Neto Bruno | Pres. of N. Am. /Europe Ops | BUY | 2,025 | $2.94 | $6.0K |
| Sep 28, 2026 | Gon Cesar Nivaldo | Chief Executive Officer | AWARD | 8,412 | $2.89 | $24.3K |
| Sep 25, 2026 | Gon Cesar Nivaldo | Chief Executive Officer | AWARD | 404 | $3.02 | $1.2K |
| Sep 24, 2026 | Guicardi Neto Bruno | Pres. of N. Am. and Europe Ops | BUY | 581 | $3.02 | $1.8K |
| Sep 23, 2026 | Guicardi Neto Bruno | Pres. of N. Am. / Europe Ops | BUY | 1,206 | $3.08 | $3.7K |
| Sep 22, 2026 | Guicardi Neto Bruno | Pres. of N. Am. / Europe Ops | BUY | 2,802 | $3.07 | $8.6K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for CINT.
Shares short
18,191
Settlement Sep 15, 2026
Change vs prior
-61.0%
Semi-monthly cycle
Days to cover
1.0
At avg daily volume
Of shares outstanding
≈0.0%
Estimate — not % of float
All CINT filing & press-release reports (1)
- 6-K reportApr 27, 2026